TTC Oncology: Treating breast cancer with safe, simple & effective therapy.

VISION: Long Term Solution for Millions of Suffering People

Debra Tonetti, Founder of TTC Oncology LLC, Professor at University of Illinois at Chicago, & experienced cancer biology researcher, was instrumental in development of biomarker for hormone resistant breast cancer. She has 25 years of experience focused on estrogen signaling pathways in breast cancer; specifically endocrine resistance and the development of novel therapeutics. She is additionally skilled in Molecular Biology and Translational Oncology.

With this extensive background in the field, she reviewed the current state of breast cancer therapeutics and imagined —

She concluded that TTC-352 is the clear choice. Now, we just need to help make this solution available to the millions of patients who will be diagnosed with Breast Cancer in the years to come.

In the US, 1 in 8 women are diagnosed with breast cancer. 75% are categorized as estrogen receptor positive, meaning the cancers react to the hormone estrogen, and that estrogen fuels the cancer growth.

Treating this type of breast cancer involves medication to block hormone action, but in nearly half of all women treated with hormone therapies, breast cancer becomes resistant. The remaining option is the traditional & toxic chemotherapy.

For those experiencing chemotherapy, it is a frightful and dreadful experience, and for the surrounding loved ones, it is extremely difficult to process. Truly, there must be a better way.

There is a better way.

At TTC Oncology, we have developed a new drug, TTC-352, which completed Phase 1 Clinical Trials with successful estrogen receptor targeting, causing complete tumor regression, and no toxic side-effects.

Our breast cancer therapy is safe, effective and administered with an oral capsule.

This is a groundbreaking advancement, and with your help, we can make this life-changing solution available to the millions of men and women who will be diagnosed with breast cancer in the years to come.

Origins of TTC-352

The origins of TTC-352 begin with Debra’s mentor, V. Craig Jordan, a scientist with American and British citizenship specializing in drugs for breast cancer treatment and prevention. Currently, he is Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University.

Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs).

In addition to the honors and awards bestowed upon him by Her Majesty Queen Elizabeth II, his is work and efforts include further recognition from the beloved Diana, Princess of Wales:

“Later, I was named the Diana, Princess of Wales, Professor of Cancer Research at Northwestern University, and Mrs. Lurie and the president of Northwestern did the honors of giving me my medal—the Diana, Princess of Wales Medal—which I’m permitted to wear on any occasion where I’m wearing academic dress. That’s the tradition. Whenever I receive honorary degrees, I wear the Diana, Princess of Wales Medal.” - Dr. Jordan

You can read the full article on V. Craig Jordan here: Article Link

It is with such great support & mentorship that TTC ONCOLOGY continues forward in their mission to help those suffering from today’s breast cancer therapeutics.

A Novel, First-in-Class, Best-in-Class Selective Human ER Partial Agonist (ShERPA) Which is Safer Than Estradiol:

Activates the estrogen signaling pathway, but differently than estradiol.
Recruits many more estradiol-enriched coactivators than SERMs.
Induces more rapid ER-induced unfolded protein response and apoptosis compared to SERMs

TTC-352 mechanism of action in hormone resistant breast cancer

Abderrahman B, et al. Rapid induction of the unfolded protein response and apoptosis by the estrogen mimic TTC-352 for the treatment of endocrine-resistant breast cancer. Author Manuscript Published OnlineFirst on November 11, 2020; DOI: 10.1158/1535-7163.MCT-20-0563.

Patents

Traction

With an IND approved by the U.S. FDA in 2017, we completed a Phase 1 human trial at four investigational sites: the University of Wisconsin Cancer Center, Madison, Wisconsin (PI: Dr. Ruth O’Regan), HonorHealth Research Institute, Scottsdale, Arizona (PI: Dr. Jasgit Sachdev), HealthPartners Institute, St. Paul, Minnesota (PI: Dr. Randy Hurley), and Sanford Research, Sioux Falls, South Dakota (PI: Dr. Jonathan Bleeker). The current Offering would be used primarily to fund Phase 2 clinical trials, which are in preparation.

PHASE 1 Results

TTC-352 was very well tolerated across all tested dose levels
TTC-352 induced remarkable disease stability in four patients (range, 112 -309 days)
Clinical evidence of biomarker predicting benefit from TTC-352

Conclusions

TTC-352 demonstrates safety and early clinical evidence of antitumor activity against heavily pretreated hormone-refractory breast cancer.
Based upon TTC-352 plasma concentrations and tolerability, the 180 mg twice a day is recommended for further testing.

You can review the full Phase 1 Study at: doi.org/10.1007/s10549-020-05787-z

Market

A $55.27B Market by 2027

According to Fortune Business Insights, the global breast cancer therapeutics market size is projected to be $55.27B by 2027, with a CAGR of 13.1%.*

It is anticipated that a drug such as TTC-352, a non-toxic and easily administered therapy, will be extremely competitive in this rapidly expanding market.

* www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163

Exit Opportunities

Pharma Purchase

Our target potential exit opportunity is through a Pharma Purchase, which illustrates a possible scenario and can not be guaranteed.

Competition

The key competitors are as follows:

Elacestrant (Menarini)
ARV-417 (Arvinas and Pfizer collaboration)
Amcenestrant (Sanofi)

TTC-352 has a key competitive advantage of being non-toxic, which speaks directly to quality-of-life, an integral distinction for those suffering from breast cancer and current therapies.

Use of Funds

Wefunder capital raised will be employed to prepare the pathway in discussion with FDA for studies needed for Drug approval, and support planned Series A funding.

Quality of life for millions
For the millions of people who will suffer the pain of current breast cancer treatments, both in the US and across the globe, the market availability of TTC-352 can not come soon enough.

Financial Rewards
For investors, getting in early is always the stronger path to greater financial rewards. TTC Oncology is on target to complete studies in 36 months followed by acquisition plans by a Pharma partner.

Special Offering
This Wefunder investment opportunity is a unique chance to invest in a promising early stage drug. Investments at a later date will most likely require a much larger investment size, and under strict Accredited Investor requirements.